Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2
Recruiting
N/A
Interventional Study
Long COVID
Insulin Resistance
Insulin Sensitivity
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 55 (estimated)
- Sponsor
- Stanford University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk fact…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Ages 18 to 80
* BMI ≥ 25 kg/m2
* not currently pregnant
Exclusion Criteria:
Arm 2 (Adipose Tissue Biopsy) exclusions include
* pregnancy
* prior liposuction
* recent change in weight (\> 2 kg in one month)
* bleeding disorders
* anticoagulant use
Arm 3 (healthy controls on…
Contacts